Efficacy and safety of incretin therapy in type 2 diabetes - Systematic review and meta-analysis

被引:834
|
作者
Amori, Renee E.
Lau, Joseph
Pittas, Anastassios G.
机构
[1] Tufts Univ New England Med Ctr, Div Endocrinol Diabet & Metab, Boston, MA 02111 USA
[2] Tufts Univ New England Med Ctr, Inst Clin Res & Hlth Policy Studies, Boston, MA 02111 USA
来源
关键词
D O I
10.1001/jama.298.2.194
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context Pharmacotherapies that augment the incretin pathway have recently become available, but their role in the management of type 2 diabetes is not well defined. Objective To assess the efficacy and safety of incretin-based therapy in adults with type 2 diabetes based on randomized controlled trials published in peer-reviewed journals or as abstracts. Data Sources We searched MEDLINE ( 1966 - May 20, 2007) and the Cochrane Central Register of Controlled Trials ( second quarter, 2007) for English-language randomized controlled trials involving an incretin mimetic (glucagonlike peptide 1 [GLP-1] analogue) or enhancer ( dipeptidyl peptidase 4 [DPP4] inhibitor). We also searched prescribing information, relevant Web sites, reference lists and citation sections of recovered articles, and abstracts presented at recent conferences. Study Selection Randomized controlled trials were selected if they were at least 12 weeks in duration, compared incretin therapy with placebo or other diabetes medication, and reported hemoglobin A(1c) data in nonpregnant adults with type 2 diabetes. Data Extraction Two reviewers independently assessed trials for inclusion and extracted data. Differences were resolved by consensus. Meta-analyses were conducted for several efficacy and safety outcomes. Results Of 355 potentially relevant articles identified, 51 were retrieved for detailed evaluation and 29 met the inclusion criteria. Incretins lowered hemoglobin A1c compared with placebo ( weighted mean difference, - 0.97% [95% confidence interval {CI}, - 1.13% to - 0.81%] for GLP-1 analogues and - 0.74% [ 95% CI, - 0.85% to - 0.62%] for DPP4 inhibitors) and were noninferior to other hypoglycemic agents. Glucagon-like peptide 1 analogues resulted in weight loss (1.4 kg and 4.8 kg vs placebo and insulin, respectively) while DPP4 inhibitors were weight neutral. Glucagon-like peptide 1 analogues had more gastrointestinal side effects ( risk ratio, 2.9 [ 95% CI, 2.0-4.2] for nausea and 3.2 [ 95% CI, 2.5-4.4] for vomiting). Dipeptidyl peptidase 4 inhibitors had an increased risk of infection ( risk ratio, 1.2 [ 95% CI, 1.0-1.4] for nasopharyngitis and 1.5 [ 95% CI, 1.0-2.2] for urinary tract infection) and headache ( risk ratio, 1.4 [ 95% CI, 1.1-1.7]). All but 3 trials had a 30-week or shorter duration; thus, long-term efficacy and safety could not be evaluated. Conclusions Incretin therapy offers an alternative option to currently available hypoglycemic agents for nonpregnant adults with type 2 diabetes, with modest efficacy and a favorable weight-change profile. Careful postmarketing surveillance for adverse effects, especially among the DPP4 inhibitors, and continued evaluation in longer-term studies and in clinical practice are required to determine the role of this new class among current pharmacotherapies for type 2 diabetes.
引用
收藏
页码:194 / 206
页数:13
相关论文
共 50 条
  • [1] Efficacy and Safety of Ertugliflozin in Type 2 Diabetes: A Systematic Review and Meta-Analysis
    Liu, Li
    Shi, Fang-Hong
    Xu, Hua
    Wu, Yue
    Gu, Zhi-Chun
    Lin, Hou-Wen
    [J]. FRONTIERS IN PHARMACOLOGY, 2022, 12
  • [2] Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis
    Liakos, A.
    Karagiannis, T.
    Athanasiadou, E.
    Sarigianni, M.
    Mainou, M.
    Papatheodorou, K.
    Bekiari, E.
    Tsapas, A.
    [J]. DIABETES OBESITY & METABOLISM, 2014, 16 (10): : 984 - 993
  • [3] Safety and Efficacy of Incretin-Based Therapies in Patients With Type 2 Diabetes Mellitus and CKD: A Systematic Review and Meta-analysis
    Howse, Patricia M.
    Chibrikova, Lyudmila N.
    Twells, Laurie K.
    Barrett, Brendan J.
    Gamble, John-Michael
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2016, 68 (05) : 733 - 742
  • [4] Loss of the Incretin Effect in Type 2 Diabetes: A Systematic Review and Meta-analysis
    Grespan, Eleonora
    Guolo, Annamaria
    Muscelli, Elza
    Ferrannini, Ele
    Mari, Andrea
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2022, 107 (07): : 2092 - 2100
  • [5] Incretin-based therapy in type 2 diabetes: An evidence based systematic review and meta-analysis
    Waldrop, Greer
    Zhong, Jixin
    Peters, Matthew
    Goud, Aditya
    Chen, Yin-Hsiu
    Davis, Stephen N.
    Mukherjee, Bhramar
    Rajagopalan, Sanjay
    [J]. JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2018, 32 (01) : 113 - 122
  • [6] Efficacy and safety of incretin-based drugs in patients with type 1 diabetes mellitus: A systematic review and meta-analysis
    Wang, Wen
    Gao, Yun
    Chen, Dawei
    Wang, Chun
    Feng, Xiaobing
    Ran, Xingwu
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2017, 129 : 213 - 223
  • [7] Efficacy and safety of tirzepatide in patients with type 2 diabetes: A systematic review and meta-analysis
    Tang, Yan
    Zhang, Lin
    Zeng, Yuping
    Wang, Xia
    Zhang, Mei
    [J]. FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [8] Efficacy and safety of dulaglutide in patients with type 2 diabetes: a meta-analysis and systematic review
    Zhang, Lin
    Zhang, Mei
    Zhang, Yuwei
    Tong, Nanwei
    [J]. SCIENTIFIC REPORTS, 2016, 6
  • [9] Efficacy and safety of canagliflozin in subjects with type 2 diabetes: systematic review and meta-analysis
    Yang, Xu-Ping
    Lai, Dan
    Zhong, Xiao-Yan
    Shen, Hong-Ping
    Huang, Yi-Lan
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 70 (10) : 1149 - 1158
  • [10] Efficacy and safety of saxagliptin in patients with type 2 diabetes: A systematic review and meta-analysis
    Men, Peng
    Li, Xiao-tong
    Tang, Hui-lin
    Zhai, Suo-di
    [J]. PLOS ONE, 2018, 13 (05):